Medical Condition News

RSS

Atherotech to showcase VAP Cholesterol Test at NLA Scientific Sessions 2010

Atherotech Inc. will exhibit its VAP® Cholesterol Test in booth #102 at the National Lipid Association (NLA) Scientific Sessions 2010. The meeting takes place May 13-16 at the Sheraton Hotel and Towers in Chicago.

13 May 2010

Regeneron Pharmaceuticals provides update on REGN727, REGN475 antibody product candidates

Regeneron Pharmaceuticals, Inc. (REGN) provided an update on two antibody product candidates in its pipeline and scheduled its first Investor Day to be held in New York City on July 15, 2010. Both product candidates, REGN727 (SAR236553) and, REGN475 (SAR164877) are being developed with sanofi-aventis under a global, strategic collaboration to discover, develop, and commercialize fully human antibodies.

13 May 2010

FDA warns of side effects from swallowing Benadryl Extra Strength Itch Stopping Gel

The U.S. Food and Drug Administration is warning consumers about potentially serious side effects from mistakenly swallowing Benadryl Extra Strength Itch Stopping Gel, an over-the-counter (OTC) product that should only be used on the skin.

13 May 2010

Melanoma is becoming increasingly common: Mayo Clinic Women's HealthSource

Melanoma -- the most serious form of skin cancer -- is becoming increasingly common, according to the May issue of Mayo Clinic Women's HealthSource.

13 May 2010

Report describes imaging features of superior mesenteric artery aneurysm

A recent case report published on May 14, 2010 in World Journal of Gastroenterology describes the imaging features of a ruptured superior mesenteric artery aneurysm,which created a giant hematoma and mimicked a pancreatic mass, with mild dilatation of main pancreatic duct.

13 May 2010

New case report addresses diagnostic significance of CT and MRI for DCF

Duodenocaval fistula is an uncommon but lethal clinical entity. The high mortality has been attributed to the difficulty of diagnosis before attempts at definitive therapy.

13 May 2010

Computerized systems can detect early eye problems related to diabetes: UI team

People with diabetes have an increased risk of blindness, yet nearly half of the approximately 23 million Americans with diabetes do not get an annual eye exam to detect possible problems.

13 May 2010

Resverlogix' Phase 2 ASSERT trial dosing complete ahead of schedule

Resverlogix is pleased to announce that the Phase 2 ASSERT clinical trial for its lead drug, RVX-208, a small molecule therapy for the treatment of atherosclerosis has now completed dosing. "The completion of dosing for our Phase 2 ASSERT trial, five months ahead of schedule and without any alterations to the dose levels of the three drug receiving cohorts, is another major step forward in the development of this important cardiovascular drug.

13 May 2010

Mayo Clinic Women's HealthSource offers information about abdominal aortic aneurysms

Abdominal aortic aneurysms have been considered mainly a man's problem. Men, more often than women, develop a weakened and bulging area in the aorta, the body's largest artery, which poses a risk of rupture. But according to the May issue of Mayo Clinic Women's HealthSource, women aren't risk free.

13 May 2010

Study evaluates cost-utility of MARS treatment in ALF patients

Numerous studies have documented the favorable effects of MARS albumin dialysis treatment on clinical and laboratory parameters and survival in liver failure patients. However, to ensure that limited resources are utilized in an ethical manner, the subjective feelings of the patient in terms of health-related quality of life and costs should also be taken into account.

13 May 2010

FDA approves Sagent's bacitracin for pneumonia and empyema

Sagent Pharmaceuticals, Inc., a privately held specialty pharmaceutical company, today announced FDA approval of bacitracin for injection, USP (bacitracin), an anti-infective product used to treat pneumonia and empyema. Bacitracin will be offered in a 50,000 MU, AP-rated, preservative-free, latex-free, single-dose vial packaged both individually and in packages of ten.

13 May 2010

Clinical Data expands PGxHealth's FAMILION tests to include two new tests to diagnose heart diseases

Clinical Data, Inc., announced today that its PGxHealth division is expanding its FAMILION family of genetic tests to include two new tests to diagnose heart diseases. With the launch of a test for Conduction Disease associated with Dilated Cardiomyopathy and a test for Short QT Syndrome, PGxHealth continues to lead the industry with the most comprehensive menu of genetic tests to diagnose or confirm familial heart diseases.

12 May 2010

Risk of venous thromboembolism is low after hepatic resection in cirrhotic patients: Researchers

Hepatocellular carcinoma is the most common primary neoplasm of the liver and often arises in the context of a chronic liver disease that impairs coagulative function. Surgical resection is the best option to cure HCC, however, surgery on cirrhotic liver may increase the risk of bleeding.

12 May 2010

Capstone Therapeutics to continue to planned 12-month endpoints in AZX100 Phase 2a clinical trials

Capstone Therapeutics announced today it has completed a limited analysis of a subset of data from the second of its two ongoing AZX100 Phase 2a clinical trials in keloid scarring. The clinical trial will continue to its planned 12-month endpoints.

12 May 2010

FDA approves Aeterna Zentaris' AEZS-108 IND for bladder cancer

Aeterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today announced that the U.S. Food and Drug Administration (FDA) has approved the Company's Investigational New Drug (IND) application for its doxorubicin targeted conjugate compound, AEZS-108, in luteinizing hormone releasing hormone (LHRH) receptor positive urothelial (bladder) cancer.

12 May 2010

Patient enrollment completed in Phase 2 clinical trial of orBec for prevention of acute GVHD

Soligenix, Inc., a late-stage biopharmaceutical company, announced today that patient enrollment has been completed in a randomized, double-blind, placebo-controlled Phase 2 clinical trial of orBec for the prevention of acute Graft-versus-Host disease after allogeneic hematopoietic cell transplantation with myeloablative conditioning regimens.

12 May 2010

Genetic variations do not improve ability to predict risk of AD: Study

Although genome-wide analysis identified two genetic variations associated with Alzheimer disease, these variations did not improve the ability to predict the risk of AD, according to a study in the May 12 issue of JAMA.

12 May 2010

Key mechanisms for delivery of LNP-encapsulated siRNAs to the liver

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today the publication of pre-clinical research in the journal Molecular Therapy revealing key mechanisms related to the systemic delivery of RNAi therapeutics using lipid nanoparticles (LNPs).

12 May 2010

Updated data from Vical's Phase 2 trial of high-dose Allovectin-7 in metastatic melanoma patients

Vical Incorporated announced the publication in the June issue of Melanoma Research of updated data from the company's Phase 2 trial of high-dose (2 mg) Allovectin-7® in patients with metastatic melanoma. A separate article in the May issue of Expert Opinion on Biological Therapy reviewed results from the Phase 2 trial and previous clinical studies of Allovectin-7®.

12 May 2010

COTI announces favourable independent pre-IND gap analysis report for novel oncology drug candidate

Critical Outcome Technologies Inc. announced today that it received a favourable Pre-Investigational New Drug (pre-IND) gap analysis report from an independent team that reviewed its novel oncology drug candidate COTI-2. This represents an important milestone as the Company draws closer to a Phase 1 clinical trial.

12 May 2010

Medical Condition News

Atherotech to showcase VAP Cholesterol Test at NLA Scientific Sessions 2010

Regeneron Pharmaceuticals provides update on REGN727, REGN475 antibody product candidates

FDA warns of side effects from swallowing Benadryl Extra Strength Itch Stopping Gel

Melanoma is becoming increasingly common: Mayo Clinic Women's HealthSource

Report describes imaging features of superior mesenteric artery aneurysm

New case report addresses diagnostic significance of CT and MRI for DCF

Computerized systems can detect early eye problems related to diabetes: UI team

Resverlogix' Phase 2 ASSERT trial dosing complete ahead of schedule

Mayo Clinic Women's HealthSource offers information about abdominal aortic aneurysms

Study evaluates cost-utility of MARS treatment in ALF patients

FDA approves Sagent's bacitracin for pneumonia and empyema

Clinical Data expands PGxHealth's FAMILION tests to include two new tests to diagnose heart diseases

Risk of venous thromboembolism is low after hepatic resection in cirrhotic patients: Researchers

Capstone Therapeutics to continue to planned 12-month endpoints in AZX100 Phase 2a clinical trials

FDA approves Aeterna Zentaris' AEZS-108 IND for bladder cancer

Patient enrollment completed in Phase 2 clinical trial of orBec for prevention of acute GVHD

Genetic variations do not improve ability to predict risk of AD: Study

Key mechanisms for delivery of LNP-encapsulated siRNAs to the liver

Updated data from Vical's Phase 2 trial of high-dose Allovectin-7 in metastatic melanoma patients

COTI announces favourable independent pre-IND gap analysis report for novel oncology drug candidate

Evolving spectrophotometry for modern biopharma workflows

Scaling B-cell cloning workflows for antibody development

Fluidics in Modern Healthcare & Medical Device Innovation

Latest News